Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-010232
Filing Date
2020-04-03
Accepted
2020-04-03 18:06:43
Documents
2
Period of Report
2020-04-03

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 2236
2 EX-24 DOCUMENT attachment1.htm EX-24 3617
  Complete submission text file 0000899243-20-010232.txt   7590
Mailing Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Zentalis Pharmaceuticals, LLC (Issuer) CIK: 0001725160 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O ZENTALIS PHARMACEUTICALS, LLC 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018
Business Address C/O ZENTALIS PHARMACEUTICALS, LLC 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 (212) 433-3791
Recurium Equity, LLC (Reporting) CIK: 0001808095 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39263 | Film No.: 20775167